Connor Clark & Lunn Investment Management Ltd. Reduces Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Connor Clark & Lunn Investment Management Ltd. cut its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 44.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,060 shares of the company’s stock after selling 38,263 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Tarsus Pharmaceuticals were worth $1,548,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TARS. Quest Partners LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $61,000. Canada Pension Plan Investment Board purchased a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter worth $114,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Tarsus Pharmaceuticals by 33.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after acquiring an additional 1,530 shares during the last quarter. Dark Forest Capital Management LP purchased a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at about $202,000. Finally, SG Americas Securities LLC increased its position in Tarsus Pharmaceuticals by 87.5% during the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after purchasing an additional 3,379 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on TARS shares. William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. The Goldman Sachs Group increased their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Finally, Oppenheimer upped their target price on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $54.20.

Tarsus Pharmaceuticals Trading Up 2.8 %

Shares of TARS stock opened at $49.66 on Wednesday. The stock has a market capitalization of $1.90 billion, a P/E ratio of -13.03 and a beta of 1.00. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $15.60 and a fifty-two week high of $52.99. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The company has a 50 day moving average price of $40.00 and a 200 day moving average price of $33.06.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.